SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
13 oct. 2023 16h28 HE
|
SciSparc Ltd
TEL AVIV, ISRAEL, Oct. 13, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced the closing of its previously announced private placement with an...
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
11 oct. 2023 09h15 HE
|
SciSparc Ltd
TEL AVIV, ISRAEL, Oct. 11, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”), today announced that it has entered into a securities purchase agreement with an...
SciSparc Granted European Patent for its Core Technology
03 oct. 2023 07h33 HE
|
SciSparc Ltd
The receipt of the patent confirms the innovation and uniqueness of the Company's technologies and strengthens its position as a leader in the cannabis space TEL AVIV, Israel, Oct. 03, 2023 ...
SciSparc Initiated Its Clinical Trial with SCI-210 in Pediatrics with Autism Spectrum Disorder
29 sept. 2023 07h45 HE
|
SciSparc Ltd
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
27 sept. 2023 07h58 HE
|
SciSparc Ltd
Following the reverse share split, the Company will have approximately 521,090 Ordinary Shares issued and outstanding TEL AVIV, Israel, Sept. 27, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
SciSparc Announces 1-for-26 Reverse Share Split
20 sept. 2023 06h30 HE
|
SciSparc Ltd
TEL AVIV, Israel, Sept. 20, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
12 sept. 2023 09h15 HE
|
SciSparc Ltd
TEL AVIV, Israel, Sept. 12, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
07 sept. 2023 09h15 HE
|
SciSparc Ltd
Initiation of trial to take place at the Tel Aviv Sourasky Medical Center, the Israeli clinical trial site TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
07 sept. 2023 06h00 HE
|
SciSparc Ltd
No Immediate Effect on Nasdaq Listing or Trading of the Company’s Ordinary Shares TEL AVIV, Israel, Sept. 07, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a...
SciSparc Ltd. Closes $1.3 Million Underwritten Public Offering
14 août 2023 12h20 HE
|
SciSparc Ltd
TEL AVIV, Israel, Aug. 14, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc” or the “Company”) today announced the closing of a firm commitment underwritten public offering with...